Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients  Vincent G. Bain, Kelly D. Kaita, Paul Marotta, Eric M. Yoshida, Mark G. Swain, Robert J. Bailey, Keyur Patel, Patrick W. Cronin, Erik Pulkstenis, John G. McHutchison, G. Mani Subramanian  Clinical Gastroenterology and Hepatology  Volume 6, Issue 6, Pages 701-706 (June 2008) DOI: 10.1016/j.cgh.2008.02.056 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Change in median ANCs and platelet counts (PLT) during the 24-week treatment duration and at weeks 4 and 12 of follow-up (FU) after completion of treatment. aP < .05. Clinical Gastroenterology and Hepatology 2008 6, 701-706DOI: (10.1016/j.cgh.2008.02.056) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 On-treatment antiviral response rates. Clinical Gastroenterology and Hepatology 2008 6, 701-706DOI: (10.1016/j.cgh.2008.02.056) Copyright © 2008 AGA Institute Terms and Conditions

Figure 3 SVR rates: overall and in genotypes (Gt) 2 and 3. Clinical Gastroenterology and Hepatology 2008 6, 701-706DOI: (10.1016/j.cgh.2008.02.056) Copyright © 2008 AGA Institute Terms and Conditions

Figure 4 Relation between SVR and baseline insulin resistance. Box-plot representation of HOMA-IR in patients with CHC who achieved SVR and those who failed to achieve SVR. aP = .002. Clinical Gastroenterology and Hepatology 2008 6, 701-706DOI: (10.1016/j.cgh.2008.02.056) Copyright © 2008 AGA Institute Terms and Conditions